As Xarelto Lawsuits Mount, Defendants Oppose Consolidation of Federally-Filed Claims, Bernstein Liebhard LLP Reports

Share Article

The Firm is evaluating Xarelto lawsuits on behalf of individuals who allegedly suffered uncontrollable internal bleeding and other serious side effects due to the use of the blood thinning medication.

Free Case Review
Our Firm has been hearing from Xarelto patients on a regular basis, all of whom are alleged to have suffered complications related to internal bleeding and other injuries. We will be monitoring this matter closely.

As Xarelto lawsuits (http://www.xareltolawsuit2015.com/) filed on behalf of patients who were allegedly injured by the blood thinning medication continue to mount in U.S. courts, Bernstein Liebhard LLP notes that the drug’s manufacturers have voiced opposition to a proposal which would consolidate all federally-filed claims in a single U.S. District Court. In responses filed with the U.S Judicial Panel on Multidistrict Litigation (JPML) on October 31st, Bayer Healthcare and Johnson & Johnson’s Janssen Pharmaceuticals subsidiary assert that allegations put forth in Xarelto lawsuits are too individualized for the purposes of consolidation. They further contend that informal coordination among the parties would be more appropriate. (In Re: Xarelto Products Liability Litigation, No. 2592)

“Our Firm has been hearing from Xarelto patients on a regular basis, all of whom are alleged to have suffered complications related to internal bleeding and other injuries. We will be monitoring this matter closely,” said Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering Xarelto case reviews to people who allegedly suffered serious injuries from the blood thinner, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.

Xarelto Litigation
Xarelto was approved for sale in the U.S. in 2011, and is now indicated to prevent strokes in people with atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery.* According to a 2013 analysis conducted by the Institute for Safe Medicine Practices, the FDA had received 2,081 reports of Xarelto complications by the end of Fiscal Year 2012, including 151 that resulted in death. By contrast, warfarin, a blood thinner that has been in use for decades, was associated with just 56 fatalities during the same time period.**

According to court documents, at least 30 Xarelto lawsuits have been filed in U.S. courts on behalf of patients who were allegedly harmed by the blood thinner. Among other things, all of these complaints allege that the medication was wrongly marketed as an improvement over warfarin. They point out that while warfarin bleeding can be stopped via the administration of vitamin K, there is currently no approved antidote to reverse internal hemorrhaging that can sometimes occur with Xarelto.

In October, six Xarelto lawsuit plaintiffs petitioned the JPML seeking the establishment of a multidistrict litigation in the U.S. District Court, Southern District of Illinois for all claims currently pending in federal courts, as well as those filed in the future. According to court documents, their petition asserted that thousands of similar claims could be filed in the near future, and that consolidation of the docket would allow the cases to proceed more efficiently through the court system.

Individuals who were allegedly harmed by Xarelto may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Xarelto lawsuit, please visit Bernstein Liebhard LLPs website, or call 800-511-5092 to schedule a free, no obligation case review.

*fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, March 2014
**ismp.org/quarterwatch/pdfs/2013Q1.pdf, Institute for Safe Medication Practices, May 7, 2014.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.xareltolawsuit2015.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website